Mirai Medical announced today that it appointed former Boston Scientific
(NYSE: BSX)
executive David A. Pierce as a non-executive board director.
Pierce spent 31 years at Boston Scientific, gaining valuable experience in product commercialization, market access and clinical change management. Much of his work came in the gastrointestinal endoscopy space, providing expertise he can now bring to Mirai Medical. Pierce retired from his post as EVP and president of medsurg and endoscopy at Boston Scientific in July 2022.
“We are thrilled to welcome David to our board,” Mirai Medical CEO Declan Soden said in a news release. “His extensive experience at Boston Scientific, coupled with his deep knowledge of the industry, will undoubtedly play a pivotal role in guiding Mirai Medical’s strategic direction. As leaders in pulsed field ablation, we are confident that Mr. Pierce’s contributions will further elevate our capabilities and impact in interventional endoscopy.”
Galway, Ireland-based Mirai Medical develops pulsed field ablation (PFA) technologies within the gastrointestinal (GI) tract. PFA has become a hotbed area of medtech, specifically for treating AFib. Mirai wants to empower every endoscopist to treat GI tract disease at diagnosis.
The company’s proprietary ePORE therapy features precise algorithmic control of PFA parameters. It enables the safe and effective treatment of pre-malignant and malignant disease across the GI tract.
“I am honored to be part of Mirai Medical, a company at the forefront of innovation in interventional endoscopy,” Pierce said. “The mission to enable every endoscopist to treat at diagnosis resonates strongly with me, and I look forward to contributing to the company’s growth and success.”